Hospital Infection Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Drug Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs and Others), Indication and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global hospital infection therapeutics market is expected to witness CAGR of 4.6% over the forecast period. The primary driving factors for the growth of the market include increasing incidence of hospital acquired infectious diseases coupled with the increasing geriatric population who are susceptible to diseases. In addition, the high number of pipeline drugs specifically developing for the hospital acquired infections and an increase in R&D investments expected to boost the market growth over the forecast period. Moreover, insufficient hospital infrastructure and low awareness on the usage of infusion systems in underdeveloped countries around the world projected to fuel the usage of hospital infection therapeutics market. However, continuous efforts by the government and healthcare providers in minimizing the hospital infections coupled with stringent regulations in the development of therapeutics is expected to hamper the market growth over the forecast period.

Scope of the Report

Hospital infection therapeutics is used to treat hospital acquired infection or nosocomial infections. These infections are acquired by the patient from other infected patients in the hospital. The drug used for treatment include antibacterial, antiviral, antifungal or others based on the infection.

By Drug Type
Antibacterial Drugs
Anti-fungal Drugs
Antiviral Drugs
Others
By Indication
Blood Stream Infections
Urinary Tract Infections
Surgical Site Infections
Pneumonia
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antibacterial Segment is expected to Grow at Significant Rate

  • Antibacterial drugs used for hospital infections are expected to grow at significant rates owing to increasing initiatives on bacterial resistance, growing incidence of bacterial hospital infections.
  • According to the World Health Organization (WHO), with 100 hospitalised patients at any given time, 10 in developed and 7 in developing countries acquire minimum one healthcare-associated infection.
  • Urinary tract infections are expected to have a notable share in indications segment and is expected to grow at significant rates. The growth is attributed to the increasing number of patients with urinary tract infections and ongoing research and development on urinary tract infection treatment.
  • Moreover, the rise in the older population and prevalence of hospital acquired infection fuelling the overall market growth over the forecast period.
Hospital Infection Therapeutics

North America Expected to have Significant Market Share

North America region is anticipated to have significant market share owing to the growing number of multidrug-resistant pathogens coupled with the presence of key market players focusing on innovating therapeutic options. According to the Center for Disease Control and Prevention (CDC), in American hospitals alone, about 1.7 million people are affected by the hospital acquired infections each year. Asia Pacific hospital infection therapeutics market is projected to have considerable growth rate owing to the presence of developing and underdeveloped healthcare centers having low awareness regarding the hospital infection control systems and growing incidence of hospital acquired infections. Moreover, companies’ interest in expanding to the unaddressed markets in the Asia Pacific region is anticipated to fuel the regional growth.

Hospital Infection Therapeutics Market -  Growth Rate by Region - Image

Competitive Landscape

Global hospital infection therapeutics market is moderately fragmented and competitive. Market players are focusing on product innovations, new product launches and regional expansions to increase their market share. The key market players operating in hospital infection therapeutics market include Merck & Co., Inc., Allergan, AstraZeneca plc, Johnson & Johnson and F. Hoffmann-La Roche AG among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for Non-Invasive Dermatology Techniques and Ageing Population

      2. 4.2.2 Increasing R&D Investments for New Hyaluronic Acid Based Dermal Fillers

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Skilled Professionals

      2. 4.3.2 High Cost of Dermal Filling Procedures

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 Antibacterial Drugs

      2. 5.1.2 Anti-fungal Drugs

      3. 5.1.3 Antiviral Drugs

      4. 5.1.4 Others

    2. 5.2 By Indication

      1. 5.2.1 Blood Stream Infections

      2. 5.2.2 Urinary Tract Infections

      3. 5.2.3 Surgical Site Infections

      4. 5.2.4 Pneumonia

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Allergan plc

      2. 6.1.2 Merck & Co., Inc.

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 AstraZeneca

      5. 6.1.5 F. Hoffmann-La Roche AG

      6. 6.1.6 Bayer AG

      7. 6.1.7 GlaxoSmithKline plc

      8. 6.1.8 Cubist Pharmaceuticals, Inc.

      9. 6.1.9 Sanofi S.A.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hospital Infection Therapeutics Market market is studied from 2018 - 2026.

The Hospital Infection Therapeutics Market is growing at a CAGR of 4.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck & Co., Inc., Allergan, AstraZeneca plc, Johnson & Johnson, F. Hoffmann-La Roche AG are the major companies operating in Hospital Infection Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!